Insmed Inc
INSM
NASDAQ
Biotechnology
$123.74
USD
-2.59 (-2.05%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $28.45B
Volume 2.0M
Revenue
$1.14B
TTM
+185.8%
YoY
Gross Margin
83%
TTM
+10.2%
YoY
Net Income
$-875.31M
TTM
+15.4%
YoY
Operating Cash Flow
$-778.92M
TTM
+7.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 107.4 | 142.3 | 263.8 | 306.0 | 425.5 |
YoY Growth | +18.9% | +52.4% | +152.6% | +229.6% | +296.1% |
Cost of Revenue | 28.1 | 29.4 | 44.2 | 47.4 | 67.2 |
Gross Profit | 79.3 | 113.0 | 219.6 | 258.5 | 358.3 |
Selling, General & Administrative | 154.8 | 186.4 | 212.5 | 247.3 | 247.5 |
Other Operating Expenses | 59.0 | 104.7 | 70.0 | -47.0 | -99.8 |
Total Operating Expenses | 392.2 | 479.0 | 539.4 | 411.9 | 359.8 |
Operating Income | -312.9 | -366.0 | -319.7 | -153.3 | -1.5 |
EBITDA | -309.1 | -362.0 | -314.2 | -148.3 | 3.7 |
Other Income / Expense | 0.5 | -0.6 | -1.8 | -0.7 | -0.5 |
Total Other Income / Expense | -7.6 | -2.7 | -7.2 | -8.8 | -9.8 |
Income Before Income Taxes | -320.4 | -368.7 | -326.9 | -162.1 | -11.4 |
Income Taxes | 1.2 | 1.3 | 1.6 | 1.5 | 1.9 |
Net Income | -321.7 | -370.0 | -328.5 | -163.6 | -13.2 |
Consolidated Net Income / Loss | -321.7 | -370.0 | -328.5 | -163.6 | -13.2 |
Net Income Attributable to Common Shareholders | -321.7 | -370.0 | -328.5 | -163.6 | -13.2 |
Basic EPS | -$1.70 | -$1.75 | -$1.53 | -$0.76 | -$0.06 |
Diluted EPS | -$1.70 | -$1.75 | -$1.53 | -$0.76 | -$0.06 |
Basic Shares Outstanding | 189.3M | 211.8M | 214.1M | 215.5M | 217.4M |
Diluted Shares Outstanding | 189.3M | 211.8M | 214.1M | 215.5M | 217.4M |